PE20131108A1 - Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina - Google Patents

Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina

Info

Publication number
PE20131108A1
PE20131108A1 PE2013000191A PE2013000191A PE20131108A1 PE 20131108 A1 PE20131108 A1 PE 20131108A1 PE 2013000191 A PE2013000191 A PE 2013000191A PE 2013000191 A PE2013000191 A PE 2013000191A PE 20131108 A1 PE20131108 A1 PE 20131108A1
Authority
PE
Peru
Prior art keywords
spyro
pyrane
cyclohexan
indol
dihydro
Prior art date
Application number
PE2013000191A
Other languages
English (en)
Inventor
Nadja Gruning
Marc Schiller
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43446583&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131108(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20131108A1 publication Critical patent/PE20131108A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION FARMACEUTICA PARA ADMINISTRACION ORAL QUE CONTIENE UN NUCLEO LIQUIDO EN DONDE SE DISPERSA EL AGENTE ACTIVO DE FORMULA (I), ENCAPSULADO POR UN MATERIAL SOLIDO, UNA FORMULACION AUTOEMULSIFICANTE Y UN TENSOACTIVO SELECCIONADO DE ESTERES DE ACIDO GRASO DE POLIOXIETILENO, ESTERES DE ACIDO GRASO PARCIAL DE POLIOXIETILENSORBITAN Y ESTERES DE ACIDO SULFURICO; DONDE DONDE R ES H O CH3. SON COMPUESTOS FAVORITOS: (1r,4r)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA, (1r,4r)-6'-FLUORO-N-METIL-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA O UNA SAL DE LOS MISMOS. DICHA FORMA DE DOSIFICACION ES UTIL EN EL TRATAMIENTO DEL DOLOR AGUDO, VISCERAL, NEUROPATICO Y CRONICO
PE2013000191A 2010-08-04 2011-08-04 Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina PE20131108A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37063410P 2010-08-04 2010-08-04
EP10008115 2010-08-04

Publications (1)

Publication Number Publication Date
PE20131108A1 true PE20131108A1 (es) 2013-10-17

Family

ID=43446583

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000191A PE20131108A1 (es) 2010-08-04 2011-08-04 Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina

Country Status (28)

Country Link
EP (1) EP2600838B1 (es)
JP (1) JP5792301B2 (es)
KR (1) KR101788535B1 (es)
CN (1) CN103153282B (es)
AR (1) AR082559A1 (es)
AU (1) AU2011287873B2 (es)
BR (1) BR112013004055A2 (es)
CA (1) CA2802767C (es)
CL (1) CL2012003584A1 (es)
CO (1) CO6640316A2 (es)
DK (1) DK2600838T3 (es)
EC (1) ECSP13012421A (es)
ES (1) ES2553742T3 (es)
HK (1) HK1183610A1 (es)
HR (1) HRP20151289T1 (es)
HU (1) HUE025322T2 (es)
IL (1) IL223881A (es)
MX (1) MX2013000980A (es)
NZ (1) NZ604662A (es)
PE (1) PE20131108A1 (es)
PL (1) PL2600838T3 (es)
PT (1) PT2600838E (es)
RS (1) RS54438B1 (es)
RU (1) RU2589830C2 (es)
SI (1) SI2600838T1 (es)
TW (1) TWI522360B (es)
WO (1) WO2012016703A2 (es)
ZA (1) ZA201209501B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2600851T3 (en) 2010-08-04 2018-06-25 Gruenenthal Gmbh PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN
US8912343B2 (en) * 2011-12-12 2014-12-16 Gruenenthal Gmbh Solid forms of (1r,4r)-6′-fluoro-(N, N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
JP6276702B2 (ja) * 2011-12-12 2018-02-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ−［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミン塩酸塩の固体形態
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
EP3253374B1 (en) 2015-02-02 2018-11-28 ratiopharm GmbH Composition comprising cebranopadol in a dissolved form
CN118286209A (zh) 2016-02-29 2024-07-05 帕克治疗公司 西博帕多的滴定
EP3613747A1 (en) * 2018-08-24 2020-02-26 Grünenthal GmbH Crystalline forms of trans-6'-fluoro-n-methyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
RU2765946C1 (ru) * 2021-03-11 2022-02-07 Графт Полимер Айпи Лимитед Система доставки сверхнасыщаемых самонаноэмульгирующихся лекарственных средств (SNEDDS) для слаборастворимых в воде фармацевтических композиций и способ ее приготовления
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5273200A (en) * 1999-05-24 2000-12-12 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz

Also Published As

Publication number Publication date
HUE025322T2 (en) 2016-02-29
HK1183610A1 (en) 2014-01-03
HRP20151289T1 (hr) 2016-01-01
KR101788535B1 (ko) 2017-10-20
TW201209059A (en) 2012-03-01
CO6640316A2 (es) 2013-03-22
JP2013532699A (ja) 2013-08-19
KR20130095270A (ko) 2013-08-27
PT2600838E (pt) 2015-11-17
RU2589830C2 (ru) 2016-07-10
ECSP13012421A (es) 2013-03-28
AU2011287873A1 (en) 2013-01-24
BR112013004055A2 (pt) 2018-04-24
RS54438B1 (en) 2016-06-30
RU2013109136A (ru) 2014-09-10
NZ604662A (en) 2014-08-29
MX2013000980A (es) 2013-02-15
ES2553742T3 (es) 2015-12-11
WO2012016703A2 (en) 2012-02-09
ZA201209501B (en) 2013-08-28
AU2011287873B2 (en) 2014-09-25
EP2600838A2 (en) 2013-06-12
CN103153282A (zh) 2013-06-12
CA2802767C (en) 2019-08-13
EP2600838B1 (en) 2015-09-16
CA2802767A1 (en) 2011-12-09
AR082559A1 (es) 2012-12-19
PL2600838T3 (pl) 2016-02-29
SI2600838T1 (sl) 2015-12-31
DK2600838T3 (en) 2015-10-05
CN103153282B (zh) 2015-08-19
CL2012003584A1 (es) 2013-02-01
TWI522360B (zh) 2016-02-21
JP5792301B2 (ja) 2015-10-07
WO2012016703A3 (en) 2012-08-16
IL223881A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
PE20131108A1 (es) Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina
PE20131096A1 (es) Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
DOP2014000159A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
PE20121699A1 (es) Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
PE20131106A1 (es) Aucforma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
PE20142353A1 (es) Ansolvatos de sal de noribogaina
NI201400142A (es) Formas cristalinas de un modulador del receptor de androgenos
AR075104A1 (es) Compuesto de piperazin-aril-purina, su uso para preparar un medicamento util para el tratamiento del dolor y composicion farmaceutica que lo comprende
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
RU2016106829A (ru) Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
CO6612268A2 (es) Heterobiaril-ciclohexil-tetraazabenzo[e]azulenos
BR112015014433A2 (pt) compostos tricíclicos
WO2014188329A3 (en) Transdermal extended dosing of pramipexole for neurological disorders
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
PE20141113A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
PE20131107A1 (es) Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina
PE20160198A1 (es) Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas
PE20142444A1 (es) Nueva composicion de alfentanilo para el tratamiento del dolor agudo
EA201001000A1 (ru) Антиоксидантное средство масляный бальзам "ювелакс"
EA201592297A1 (ru) Композиции агомелатина, содержащие агомелатин в форме сокристаллов
NI201200196A (es) Agentes terapéuticos 976

Legal Events

Date Code Title Description
FC Refusal